Our Approach

our approach

Our advisory work starts from a position of respect
for our clients' organization, people,
products and science.

OUR RELATIONSHIPS

our approach

We have devoted our careers to the life
sciences industry and have the deepest respect
and admiration for the participants in it.

OUR TRACK RECORD

our approach

We are a very active advisor in the market.
Torreya Partners has successfully closed over
100 assignments since our founding in 2007.

Our Perspective

our approach

We often take an operating perspective
to strategic and transaction work.

cCam Therapeutics

Sale to Merck

Up to $605 million

July 2015

Asia, Africa, MidEast, Latin America

Teva

Sale of 22 generic products to ANI Pharmaceuticals

$25 million

July 2015

North America

ProSolus

Sale to Mission Pharmacal

June 2015

North America

August 19-21, 2015

SALSS

Stockholm, Sweden

August 29 - September 2, 2015

ESC Congress

London, UK

September 2-3, 2015

Goldman Sachs Medtech and Healthcare Conference

London, UK

July 28, 2015

Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics

MORE

July 13, 2015

ANI Pharmaceuticals Acquires 22 Generic Drug Products from Teva Pharmaceuticals for $25 million

MORE

June 9, 2014

Mission Pharmacal Acquires ProSolus Pharmaceuticals

MORE